WHO vaccine-preventable diseases: monitoring system. 2020 global summary

Last updated 15-July-2020 (data as of 12-October-2020)
Next overall update End 2020

Select a country


Development status:	Developed economy	GNI / capita (US$):	27'710¹	Infant (under 12 months) mortality rate:	2²
Development status:	Developed economy	GDP / capita (US$):	41'254¹	Child (under 5 years) mortality rate:	3²

					2019	2018	2017	2016	2015	2000	1990	1980

Population data in thousands³
Total population					1'199	1'189	1'180	1'170	1'161	943	767	685
Births					12	12	13	13	13	12	15	14
Surviving infants					12	12	13	13	13	12	15	13
Pop. less than 5 years					65	65	65	66	66	68	70	60
Pop. less than 15 years					200	200	199	197	196	211	195	171
Female 15-49 years					305	305	306	306	307	244	192	178

Number of reported cases							(Click for retrospective incidence data for Cyprus)
Diphtheria					0	0	0	0	0	0	0	0
Japanese encephalitis					_	_	0	_	_	_	_	_
Measles***					6	15	3	0	0	0	4	0
Mumps					0	3	2	1	2	0	_	_
Pertussis					2	0	17	2	2	6	4	0
Polio*					0	0	0	0	0	0	0	0
Rubella***					0	0	0	0	0	0	_	_
Rubella (CRS)					0	0	0	0	0	0	_	_
Tetanus (neonatal)					0	0	0	0	0	0	0	0
Tetanus (total)**					0	1	0	0	0	0	0	0
Yellow fever					0	0	0	0	0	0	_	_
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]). Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system. * For 2019, if a country did not submit a joint reporting form, measles and rubella cases were sourced from data reported through the monthly surveillance data available from: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/measles_monthlydata/en/

Percentage target population vaccinated by antigen							Hovering over an antigen reveals its fuller definition
	Most recent coverage survey⁴					Official country estimates⁵
							(Click for retrospective coverage estimates data for Cyprus)
Vaccine	year	result	method	% card seen
BCG					_	_	_	_	_	_	_	_
DTP1					99*	99*	99*	99*	99*	99*	_	_
DTP3					96	99	97	97	97	97	_	34
IPV1					99*	99*	99*	99*	99*	_	_	_
HepB_BD					_	_	_	_	_	95	_	_
HepB3					94	97	97	97	97	89	_	_
Hib3					92	97	96	96	97	32	_	_
JapEnc					_	_	_	_	_	_	_	_
MCV1					86	90	90	90	90	86	_	29
MCV2					_	_	_	_	_	_	_	_
MenA					_	_	_	_	_	_	_	_
PCV1					99	_	98	98	98	_	_	_
PCV2					95	_	95	95	95	_	_	_
PCV3					_	_	81	81	81	_	_	_
Pol3					96	97	97	97	97	97	_	35
Rota1					_	_	_	_	_	_	_	_
RotaC					_	_	_	_	_	_	_	_
RCV1					86	90	90	90	90	_	_	_
TT2plus					_	_	_	_	_	_	_	_
PAB					_	_	_	_	_	_	_	_
VAD1					_	_	_	_	_	_	_	_
YFV					_	_	_	_	_	_	_	_
* indicates the country reported above 100% coverage.

			Next update: Mid July 2021			WHO-UNICEF estimates⁶
							(Click for full retrospective WHO-UNICEF coverage estimates data for Cyprus)
DTP1					98	99	98	98	98	98	97	59
DTP3					96	99	97	97	97	97	93	34
HepB3					94	97	97	97	97	89	_	_
HepB_BD					_	_	_	_	_	_	_	_
Hib3					92	97	96	96	97	32	_	_
IPV1					99	99	99	99	99	_	_	_
MCV1					86	90	90	90	90	86	77	29
MCV2					88	88	88	88	88	_	_	_
PCV3					81	81	81	81	81	_	_	_
Pol3					96	97	97	97	97	97	94	35
RCV1					86	90	90	90	90	86	77	29
RotaC					_	_	_	_	_	_	_	_

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country	5	Proportion of districts reporting DTP3 coverage:
% of coverage reports received at national level vs number of reports expected	100

/ \| \| \
	Greater or equal to 90%	100
	From 80 to 89%	0
	From 50 to 79%	0
	Less than 50%	0
Proportion of districts not reporting DTP3 coverage		0

Vaccine	Schedule	Entire country	Comment

Immunization Schedule^{(2019 or latest available)}		Hovering over an antigen reveals its fuller definition
BCG		Yes	persons with continuous contact with a contagious form of TB
DTaPIPV	2, 4, 6, 15-18 months; 4-6 years;	Yes
HepA_Adult		Yes	special indications
HepB_Adult		Yes	recommended for all people if not being vaccinated in childhood
HepB_Pediatric	2, 4, 8-12 months;	Yes
HIB	2, 4, 6, 12-18 months;	Yes
HPV	12-13 years; +6 months;	Yes	females; of 1st grade of secondary schools
Influenza_Adult	>65 years;	Yes	and adults with chronic conditions, pregnant women after 1st trimester, healthcare workers, residents living in long-term care facilities, Hajj and other travellers, other risk groups
Influenza_Pediatric		Yes	children with chronic conditions
IPV		Yes	booster dose for travelleres where recommended
MenC_conj	12-13 months;	Yes
MMR	12-15 months; 4-6 years;	Yes
Pneumo_conj	2, 4, 12-15 months;	Yes
Pneumo_ps		Yes	high-risk groups
Td		Yes	adult booster doses every 10 years
Tdap	14 years;	Yes	and adults
Typhoid_conj		Yes	travellers when indicated
Varicella	13 months; 4 years;	Yes	although varicella vaccine is included in the national immunization schedule, the vaccine is not provided by the government and is only available in the private sector
YF		Yes	travellers to endemic areas

Indicator	Expected answer	2019	2018	2017	2016	2015	2014	2013

Immunization indicators

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization?	Yes/No/NR	No	No	Yes	Yes	Yes	Yes	Yes
What years does the MYP cover?	number			2016-2017	2'017	2'015	2'014	2'013

System performance

Total Nº districts in country	number	5	5	5	5	5	5	6
Nº districts with DTP3 coverage >=80%	number	5	5	5	5	5	5	5
% of districts with DTP3 coverage >=80%	From 0 to 100%	100	100	100	100	100	100	83
Nº districts with measles (MCV1) coverage >=95%	number	1	1	1	1	1	1	1
% of districts with MCV1 coverage >=95%	From 0 to 100%	20	20	20	20	20	20	17

Safety

Has the country a vaccine adverse events review committee?	Yes/No/NR/ND	Yes	Yes	Yes	No	No
Is there a national system to monitor adverse events following immunization (AEFI)?	Yes/No/NR	Yes	Yes	Yes	Yes	Yes

Finance

% of Immunization expenditure financed, using Government funds?	From 0 to 100%

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)?	Yes/No/NR	No	No	No	No	No	No	No

Sources

1 "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.

2 UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)

3 "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.

4 UNICEF/WHO survey database

5 If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.

6 WHO-UNICEF estimates.

WHO vaccine-preventable diseases: monitoring system. 2020 global summary

Select a country

Population data in thousands3

Number of reported cases

Percentage target population vaccinated by antigen

Official country estimates5

WHO-UNICEF estimates6

Immunization Schedule (2019 or latest available)

Immunization indicators

Sources

Population data in thousands³

Official country estimates⁵

WHO-UNICEF estimates⁶

Immunization Schedule^{(2019 or latest available)}